François Bénard, Sara Harsini, Don Wilson, Katherine Zukotynski, Gad Abikhzer, Eric Turcotte, Mariève Cossette, Ur Metser, Jonathan Romsa, Montgomery Martin, Colin Mar, Fred Saad, Jean-Paul Soucy, Bernhard J Eigl, Peter Black, Andra Krauze, Steven Burrell, Alan Nichol, Jean-Claude Tardif
BACKGROUND: Detection of skeletal metastases in patients with prostate cancer or breast cancer remains a major clinical challenge. We aimed to compare the diagnostic performance of 99m Tc-methylene diphosphonate (99m Tc-MDP) single-photon emission CT (SPECT) and 18 F-sodium fluoride (18 F-NaF) PET-CT for the detection of osseous metastases in patients with high-risk prostate or breast cancer. METHODS: MITNEC-A1 was a prospective, multicentre, single-cohort, phase 3 trial conducted in ten hospitals across Canada...
December 2022: Lancet Oncology